ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0917

Role of Immunoglobulin Polygenic Risk in Systemic Lupus Erythematosus

Victor Gothefors-Holm1, Sarah Reid1, Ahmed Sayadi1, Maija-Leena Eloranta1, Martina Frodlund2, Karoline Lerang3, Andreas Jonsen4, Solbritt Rantapää-Dahlqvist5, Anders Bengtsson4, Anna Rudin6, Oyvind Molberg3, Christopher Sjöwall2, Johanna Sandling1, Lars Rönnblom1 and Dag Leonard1, 1Rheumatology, Department of Medical Sciences, Uppsala University, Uppsala, Sweden, 2Department of Biomedical and Clinical Sciences, Division of Inflammation and Infection/Rheumatology, Linköping University, Linköping, Sweden, 3Department of Rheumatology, Oslo University Hospital, Oslo, Norway, 4Rheumatology, Department of Clinical Sciences, Lund University, Lund, Sweden, 5Department of Public Health and Clinical Medicine/Rheumatology, Umeå University, Umeå, Sweden, 6Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden

Meeting: ACR Convergence 2023

Keywords: Autoantibody(ies), genetics, Systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 13, 2023

Title: (0899–0933) SLE – Etiology & Pathogenesis Poster

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic systemic autoimmune disease partly characterized by production of autoantibodies, causing inflammation and tissue damage. In this study we investigated whether cumulative genetic risk for elevated immunoglobulin G (IgG)-levels in the general population, represented by an IgG polygenic risk score (IgG-PRS) is associated with an increased risk of SLE, clinical manifestations or autoantibody-profile.

Methods: Patients with SLE, fulfilling the ACR-82, ACR-97 or SLICC-2012 criteria (n=1532) and healthy controls (n=1947) were genotyped using Illumina’s Global Screening Array. Clinical data was retrieved from medical charts. A weighted IgG-PRS was assigned to each individual including 13 single nucleotide polymorphisms (SNPs) associated with elevated IgG-levels in the general population, as reported by Jonsson et al. (1). Next, two sub-PRSs were developed to investigate the SLE and non-SLE genetic effect of the IgG-PRS, one including SLE-associated SNPs (r2 > 0.2, n=5) and another including non-SLE associated SNPs (n=8), table 1. Multiple logistic- and linear regression analyses were performed, adjusting for sex and SLE-duration. P-value < 0.05 was considered significant.

Results: The IgG-PRS did not differ between SLE patients and healthy controls or between men and women (both p >0.05). Out of the ACR-82 criteria, high IgG-PRS was most significantly associated with increased prevalence of arthritis (OR 4.39 (1.13-17.09), p=0.033), table 2. Further, a high IgG-PRS was associated with a greater number of different types of autoantibodies including anti-SSA, anti-SSB, anti-RNP, anti-Sm, anti-dsDNA and anti-cardiolipin antibodies (p=0.02). When investigating the autoantibodies separately, a high IgG-PRS was associated with higher prevalence of anti-SSB (OR 4.39 (1.06-18.19), p=0.04) and lower prevalence of anti-RNP (OR 0.19 (0.043-0.85), p=0.03) antibodies. In total, 38% of the SNPs included in the IgG-PRS were in linkage disequilibrium with SLE-associated SNPs (r2 = 0.26-0.96). Separating the SLE and non-SLE genetic effect for the IgG PRS, demonstrated a positive association for the SLE associated IgG PRS, and conversely a negative association for the IgG PRS excluding SLE associated SNVs (OR 22.2(8.06-61.30), p˂0.001 and OR 0.17(0.06-0.44), p ˂0.001, respectively), table 2.

Conclusion: The cumulative effect of genetic variants affecting IgG-levels in the general population is associated with both the type and the number of different autoantibodies in SLE. Investigating common genetic variants linked to immunological functions in the general population may provide further insight into the genetics driving SLE. References: < !1. Jonsson S, Sveinbjornsson G, de Lapuente Portilla AL et al.Identification of sequence variants influencing immunoglobulin levels. Nature Genetics 49(8):1182-1191, 2017.

Supporting image 1

Supporting image 2


Disclosures: V. Gothefors-Holm: None; S. Reid: None; A. Sayadi: None; M. Eloranta: None; M. Frodlund: None; K. Lerang: None; A. Jonsen: None; S. Rantapää-Dahlqvist: None; A. Bengtsson: None; A. Rudin: AstraZeneca, 12, financial support; O. Molberg: None; C. Sjöwall: None; J. Sandling: None; L. Rönnblom: None; D. Leonard: None.

To cite this abstract in AMA style:

Gothefors-Holm V, Reid S, Sayadi A, Eloranta M, Frodlund M, Lerang K, Jonsen A, Rantapää-Dahlqvist S, Bengtsson A, Rudin A, Molberg O, Sjöwall C, Sandling J, Rönnblom L, Leonard D. Role of Immunoglobulin Polygenic Risk in Systemic Lupus Erythematosus [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/role-of-immunoglobulin-polygenic-risk-in-systemic-lupus-erythematosus/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/role-of-immunoglobulin-polygenic-risk-in-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology